This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Burden of Disease
Burden of Disease
Risk Factors
Secondary Infections
Mechanism of Action
Prevention of Pneumococcal Disease
Need for Pneumococcal Vaccination
Cost-effectiveness of PCV13
Legacy of Prevenar
Safety
Conclusion
Dosing
Prevenar 13® Clinical Experience
Efficacy of Prevenar 13®
Effectiveness of Prevenar 13®
Indian Clinical Trials
Recommendations for Use
PCV13 in Pulmonology
PCV13 in Nephrology
PCV13 in Oncology
PCV13 in Rheumatology
PCV13 in Diabetes
PCV13 in HIV Infection
PCV13 in Cardiology
Resources
Prevenar 13® (PCV13) has been evaluated in 6 pivotal clinical trials in 6198 patients ≥50 years of age (of which 5667 patients received at least 1 dose of Prevenar 13® [PCV13]).1,2 The immune responses were evaluated using the OPA as the primary evaluation parameter, which is a better correlate of the functional efficacy of antibodies. This is important for older adults, because the antibodies generated by vaccination may not always be functional, due to the changes in immunosenescence.3,4
Sanford et al reviewed the immunogenicity studies of PCV13 in adults; a total of 6 studies were reviewed. All 6 studies were randomised multicentre trials. Participants in these studies were either healthy adults or immunocompetent adults with chronic medical conditions and were either PPSV23 vaccine–naïve or vaccinated with PPSV23 at least 5 years earlier to the study. In the case of pneumococcal vaccine–naïve adults 60 to 64 years of age and adults ≥70 years of age who were previously vaccinated, the immune response provoked by PCV13 was non-inferior to that of PPSV23. For the majority of serotypes common to both PCV13 and PPSV23, PCV13 provoked a stronger immune response as compared with PPSV23. As compared with PPSV23 which does not include serotype 6A, more PCV13 recipients had a ≥4-fold increase in serotype 6A OPA GMTs. Recipients of PCV13 met superiority criteria for most serotypes. For adults 50 to 59 years of age, the immune response to PCV13 was non-inferior to that observed in adults 60 to 64 years of age. Administration of PCV13 and PPSV23 in different sequences indicated that PCV13 should be administered first, followed by PPSV23. The adverse events, such as muscle pain, swelling, headache, rash and chills, within 14 days of vaccination, were of mild-to-moderate severity. Serious adverse events were observed in 0.4% to 1.7% of PPSV23 recipients and 0.2% to 1.4% of PCV13 recipients.2
GMT, geometric mean titre; OPA, opsonophagocytosis assay; PCV, pneumococcal conjugate vaccine; PPSV23, 23-valent pneumococcal polysaccharide vaccine; PPSV13, 13-valent pneumococcal polysaccharide vaccine.
References:
Please click the Prescribing Information link to view the safety and adverse events information of Prevenar 13®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-PRV-IND-0268 July 2022
Help protect your adult patients against pneumococcal pneumonia with single-dose administration
Learn more
The ACIP recommends routine use of PCV13 among adults
Learn more
FAQs related to different fields
Learn more
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.